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Background: The relative efficacy and safety of percutaneous coronary 
intervention (PCI) with drug-eluting stents (DES), in comparison to coronary 
artery bypass grafting (CABG) for left main coronary artery disease (LMCAD) 
remains controversial. 
Methods: We performed a meta-analysis of randomised studies comparing 
patients with LMCAD treated with PCI with DES versus those treated with CABG, 
with respect to clinical outcomes at 1, 3 and 5 years. A secondary meta-analysis 
was performed according to low (<32), or high (≥33) SYNTAX score. 
Results: Five studies comprising 4595 patients were included. There was no 
significant difference in all-cause death at all time points or when stratified with 
respect to SYNTAX score. The need for repeat revascularization was significantly 
higher with PCI at all time-points, and regardless of SYNTAX score. There was 
significant association between need for repeat revascularization with PCI and 
diabetics (p=0.04). At 5 years, non-fatal MI was higher with PCI owing to increased 
non-procedural events (OR 3.00; CI 1.45-6.21; p=0.003). CABG showed higher rate 
of stroke at 1 year (OR 0.21; CI 0.07-0.63; p=0.005). There was no difference in 
non-fatal MI or stroke at other time points, nor according to SYNTAX score.  
Conclusions: PCI with DES or CABG are equivalent strategies for LMCAD up to 5 
years with respect to death, regardless of SYNTAX score. PCI increases the rate of 
non-procedural MI at 5 years. CABG avoids the need for repeat revascularization, 
especially in diabetics, but this benefit is offset by higher rate of stroke in the first 
year of follow up.  
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CABG = coronary artery bypass grafting  
DAPT = dual antiplatelet therapy 
DES = drug-eluting metal stents 
LMCAD = left main coronary artery disease 
MACCE = major adverse cardiovascular and cerebrovascular events  
MI = myocardial infarction 






Coronary artery bypass grafting (CABG) is considered the gold standard for the 
vast majority of patients with left main coronary artery disease (LMCAD) [1, 2]. 
However, over the past decade, there have been a number of studies reporting 
comparable results between percutaneous coronary intervention (PCI) with drug-
eluting stents (DES) and surgical revascularization for the treatment of LMCAD [3-
5]. This has been attributed to advances in stent technology, intra-procedural 
imaging allowing stent optimization, as well as advances in pharmacotherapy to 
reduce peri-procedural and long term thrombosis risk and restenosis. 
Consequently, there has been uncertainty regarding the optimal revascularization 
strategy, especially in light of the recent publication of two additional dedicated 
multi-centre randomised trials of LMCAD [6, 7].  
Although previous meta-analyses comparing PCI with DES and CABG have 
demonstrated equipoise between the two strategies, the analyses included 
observational data [3-5]. A recent meta-analysis of randomised trial data from the 
longest available follow-up has demonstrated no difference in clinical outcomes 
between PCI with DES and CABG in patients with LMCAD [8]. Our aim was to 
perform a comprehensive systematic review and meta-analysis of randomised 
clinical trials in order to evaluate clinical outcomes at short (1 year), medium (3 
years) and long (5 years) follow-up duration, and stratify according to coronary 
disease complexity using the SYNTAX (Synergy Between Percutaneous Coronary 






Study objectives and design  
The outcomes of interest were all-cause death, non-fatal myocardial infarction 
(MI), repeat revascularization, stroke, defined according to the original study 
protocols, at 1, 3 and 5 years. We also performed a secondary meta-analysis 
according to SYNTAX score, bimodally classified as low (<32) or high SYNTAX 
score (≥33) at maximum follow-up duration. A SYNTAX score cut-off of more than 
33 was found to be useful in distinguishing high risk patients after PCI [9, 10]. 
Inclusion criteria were randomised controlled trials comparing PCI with DES 
versus CABG for LMCAD, and reporting clinical outcomes. The study was designed 
according to the PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-analyses) statement [11] and Cochrane methodology [12]. A complete 
PRISMA 2009 checklist has been followed to guide reporting of our meta-analysis. 
Study search strategy  
 
Using Medline, Embase, Scopus, and the Cochrane Library, we performed searches 
of articles published until December 2016, without language restrictions. Eligible 
studies were identified using various combinations of the terms: left main, drug-
eluting stent, percutaneous, coronary, myocardial infarction, angina, angioplasty, 
bypass, grafting, and intervention in the abstract or title. Reference lists of the 
retrieved articles were reviewed to identify further eligible studies. When two 
similar studies were reported from the same institution, the most recent 
publication was included in the analysis. Two reviewers independently reviewed 
all titles, or titles and abstracts from the search results to identify articles 
according to fulfillment of inclusion criteria. Selected trials were compared, and 
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disagreement was resolved by team discussion and consensus. Studies were 
excluded from the meta-analysis if they were duplicates, single-arm studies or 
included the use of bare-metal stent.  
Data extraction  
 
Data extraction was carried out independently and in duplicate by the study 
investigators. Results of data extraction were then compared, and discrepancies 
resolved by consensus. If results were incomplete or unclear, the study authors 
were contacted. Articles selected for the final review were checked to avoid 
inclusion of data published in duplicate. Data were collated from each study 
regarding baseline characteristics, including sample characteristics, dual 
antiplatelet duration, stent type, EuroSCORE, SYNTAX score, and clinical outcomes 
at 1, 3 and 5 years. All outcomes were defined according to the original study’s 
protocol definition [Supplemental Table 1]. If target vessel revascularization was 
not reported, we used all repeat revascularizations instead. All-cause death data 
were used in the analysis, as cardiovascular death data were incomplete at our 
chosen time points of interest. Of note, peri-procedural MI was included in 4 trials 
[7, 9, 13, 14], whereas 1 trial only assessed non-procedural MI [6]. 
Statistical analysis 
 
Pooled odds ratio (OR) with 95% confidence interval (CI) were estimated for 
binary variables using a random-effects model by the method of DerSimonian and 
Laird [15]. A pooled analysis of the hazard ratio with 95% CI was also reported 
[Supplemental Table 2]. Heterogeneity between individual studies was explored 
by X2 statistic and characterized with I2 statistic. In sensitivity analysis, we 
included only studies that included patients who had non-procedural MI at 5 
years. We examined the following relationships; (1) the log-transformed OR of the 
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effect of PCI with DES on repeat revascularization risk and the log-transformed 
OR of the effect of PCI with DES on non-fatal MI risk at maximum follow-up 
duration, (2) the log-transformed OR of the effect of PCI with DES on repeat 
revascularization risk at maximum follow-up duration and the trial reported 
percentage of distal bifurcation or trifurcation involvement, and (3) the log-
transformed OR of the effect of PCI with DES on repeat revascularization risk at 
maximum follow-up duration and the trial reported percentage of patients with 
diabetes mellitus. 
The results from meta-analysis were shown using forest-plot. Publication bias was 
minimised by a comprehensive and inclusive literature search. In addition, funnel 
plot was used to investigate publication bias. All tests were two-sided, and 
statistical significance was fixed at 0.05 level. Analysis was carried out using 
Review Manager Software (RevMan V. 5.3) and Stata V. 11.2 (StataCorp, College 












Five randomised trials involving a total of 4595 patients were identified [6, 7, 9, 
13, 14], which directly compared the clinical outcomes of PCI with DES, and CABG 
in patients with LMCAD [Supplemental Figure 1]. The methodological quality of 
included studies is described in Supplemental Table 3. The primary outcomes of 
included studies are listed in Supplemental Table 4. There was no evidence of 
publication bias having a significant effect on the results [Supplemental Figure 2]. 
The characteristics of randomised trials are listed in Supplemental Table 5. 
Greater than three-quarters of patients were male with a mean age of 65±2 years, 
25.4% were diabetics, and 34.8% received first generation DES. Of the 2297 
patients randomised to receive PCI with DES, stent types were: first generation 
paclitaxel-eluting stents (n=359), first generation sirolimous eluting stents 
(n=440), second generation biolimus-eluting stents (n=550), and second 
generation everolimus-eluting stent (n=948). The maximum follow-up duration 
for all studies was a median of 5 years. 
There was no significant difference in all-cause mortality between PCI and CABG 
at 1 year (OR 0.70; CI 0.44-1.12; p=0.14) [Figure 1 A], 3 years (OR 1.14; CI 0.73-
1.80; p=0.56) [Figure 1 B], or 5 years (OR 0.92; CI 0.69-1.24; p=0.60) [Figure 1 C], 
and with low (OR 0.89; CI 0.47-1.71; p=0.74), or high (OR 0.88; CI 0.19-3.95; 
p=0.86) SYNTAX score [Supplemental Figure 3]. 
There was no difference in the incidence of non-fatal MI between PCI and CABG at 
1 year (OR 1.17; CI 0.70-1.95; p=0.55) [Figure 2 A], or 3 years (OR 1.21; CI 0.65-
2.26; p=0.54) [Figure 2 B]. However, at 5 years, non-fatal MI was higher with PCI 
(OR 2.04; CI 1.30-3.19; p=0.002) [Figure 2 C], owing to an increased rate of non-
procedural MI (OR 3.00; CI 1.45-6.21; p=0.003) [Supplemental Figure 4]. There 
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was no difference in the incidence of non-fatal MI between PCI and CABG with low 
(OR 1.24; CI 0.67-2.29; p=0.49), or high (OR 1.86; CI 0.82-4.24; p=0.14) SYNTAX 
score [Supplemental Figure 3]. 
The need for repeat revascularization was significantly higher with PCI with DES 
compared to CABG, consistent across each follow up time point; at 1 year (OR 2.51; 
CI 1.57-4.02; p<0.001) [Figure 3 A], 3 years (OR 1.84; CI 1.43-2.37; p<0.001) 
[Figure 3 B], 5 years (OR 1.86; CI 1.45-2.38; p<0.001) [Figure 3 C], and with low 
(OR 1.69; CI 1.31-2.17; p<0.001), or high (OR 3.75; CI 2.14-6.57; p<0.001) SYNTAX 
score [Supplemental Figure 3]. 
CABG significantly increased the rate of stroke at 1 year (OR 0.21; CI 0.07-0.63; 
p=0.005) [Figure 4 A], but not at 3 years (OR 0.51; CI 0.19-1.40; p=0.19) [Figure 4 
B], 5 years (OR 0.93; CI 0.24-3.64; p=0.92) [Figure 4 C], or with low (OR 0.72; CI 
0.42-1.22; p=0.22), or high (OR 0.32; CI 0.08-1.33; p=0.12) SYNTAX score 
[Supplemental Figure 3].  
At maximum follow-up duration, there was significant association between repeat 
revascularization risk with PCI with DES and the trial reported percentage of 
patients with diabetes (p=0.04) [Supplemental Figure 5], but not with non-fatal 
MI risk (p=0.23) [Supplemental Figure 6], nor the trial reported percentage of 




The major findings of our review suggest that, in selected patients, PCI is a safe 
and durable alternative to CABG at short-term follow-up in patients with LMCAD. 
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PCI increased the incidence of non-procedural MI at 5 years, a result that merits 
further investigation, as it is driven by a single study. The absence of benefit of 
CABG over PCI in terms of mortality or stroke, at all time points and even at 5 years 
from the index procedure, suggests that the increased rate of repeat 
revascularization in the PCI arm does not translate into clinical harm, compared 
with CABG. In our analysis, CABG was associated with an increased risk of stroke 
at one year follow-up, yet this risk was abated at longer follow-up period. This 
result is in line with previous analyses of LMCAD patients undergoing CABG [4, 
16]. This is an important issue because patients, and many cardiologists, may be 
willing to accept the trade-off between the need for repeat revascularization with 
PCI in order to avoid the potential early risk of stroke with CABG. The early 
increased risk of stroke peri-operatively with CABG is likely multifactorial, related 
to cerebral embolism, hypoperfusion injury, surgical manipulation of the great 
vessels, or perioperative atrial fibrillation [17]. Furthermore, PCI is also more 
attractive to patients with its minimally invasive approach and shorter length of 
hospital stay.  
In the era of bare-metal stent, the LE MANS randomised trial of 105 patients with 
LMCAD and low SYNTAX score showed that PCI was associated with favourable 
outcomes up to 10 years compared to CABG [18]. The results of two landmark 
studies were recently published. The NOBLE trial suggests that CABG might be 
better than PCI with DES for the treatment of LMCAD at 5 years follow-up (6). 
However, the EXCEL trial shows that PCI with DES was non-inferior to CABG at 3 
years follow-up (7).  
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Equipoise in short to medium term outcomes between the two strategies in our 
analysis was independent of coronary disease complexity, as assessed with the 
SYNTAX score. In other words, PCI with DES in LMCAD patients may be suitable 
for low- as well as select high-risk PCI patients. However, this conclusion must be 
moderated by the fact that the trials included only a small number of patients with 
a high SYNTAX score. First-generation DES were used in about 35% of patients, 
and have been associated with an increased risk of very late stent thrombosis (>1 
year) [19]. This may have contributed to the increased risk of non-procedural MI 
with PCI at 5 years. Despite this increased risk, our analysis shows an equivalence 
of PCI with DES and CABG strategies for up to 5 years with respect to mortality. 
As might be expected, our analysis shows that PCI is associated with increased 
rate of repeat revascularization when compared to CABG at all follow-up 
durations, independent of SYNTAX score. This seems to be consistent amongst all 
included trials, and regardless of first or second generation DES [Figure 3]. 
However, counter-intuitively, this need for increased revascularization was not 
related to more complex coronary anatomy (such as distal bifurcation or 
trifurcation), nor was it associated with an increase risk of MI. What drives the 
difference in our analysis seems to be the beneficial effect of CABG on reducing the 
need for repeat revascularization. Of note, although graft failure is common, 
occurring in up to 43% of patients post-CABG during the first 4 years from surgery 
[20], this does not always lead to revascularization probably because it is clinically 
silent in many patients; in part due to the preservation of collateral flow through 
the native vessel, in stark contrast to the typical ST-elevation MI presentation of 
acute stent occlusion. Moreover, the routine use of the internal mammary artery 
in CABG can provide very long-term patency rates.  
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The need for repeat revascularization was found to be associated with PCI with 
DES for LMCAD in patients with diabetes. This is not surprising since these 
patients generally have a great burden of atherogenic risk factors, and disease 
burden [21]. This is supported by previous studies showing that CABG achieved 
more favorable outcomes compared with PCI in diabetic patients [22]. Thus, with 
few exceptions, CABG should therefore remain the preferred treatment option in 
diabetics with LMCAD.  
The utility of the SYNTAX score for selecting PCI versus CABG in LMCAD is 
uncertain and may not be important [23]. As with most coronary angiographic 
disease complexity scores, it does not incorporate clinical factors or the functional 
significance of the stenosis. Available data suggests a SYNTAX score threshold of 
34 to identify patients who benefit most from CABG [9, 10]. Our meta-analysis of 
randomised trial data, however, is hypothesis generating, and suggests that 
clinical safety outcomes, including mortality, may not differ between 
percutaneous or surgical revascularization strategies based on the SYNTAX score.   
There are several reasons why the trials included in this analysis are not directly 
comparable. The use of intravascular ultrasound in PCI patients varied 
significantly between trials [Supplemental Table 5], with about a third of patients 
not receiving this optimization modality. There is abundant evidence that 
intravascular ultrasound decreases stent thrombosis, restenosis, and 
revascularization rates [24, 25]. We believe that intravascular ultrasound 
guidance during PCI of LMCAD is necessary to optimize stent expansion and 
ensure full lesion coverage and achieve optimal long-term outcomes. The duration 
of dual antiplatelet therapy (DAPT), the mainstay treatment post PCI to minimise 
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stent thrombosis and MI risk [26], varied between 6 and 12 months in included 
trials. Recently, there has been much controversy concerning the optimal duration 
of DAPT with many supporting long-term (>1 year) therapy, especially following 
left main angioplasty or complex PCI to reduce ischemic outcomes [27, 28]. 
Further studies are needed to evaluate the clinical outcome of PCI with DES with 
longer DAPT duration. 
Our study has several limitations. Firstly, we did not have access to patient-level 
data. Availability of individual patient data could improve the reliability of the 
findings and permit more flexible analyses. Secondly, variable definitions of 
clinical outcomes by the primary studies may have introduced detection bias. The 
definition of repeat revascularization slightly differed between trials. Target 
vessel revascularization rates and cardiovascular death rates were not reported 
in all trials. The definition of MI also differed between trials and non-procedural 
MI events were unavailable. Thirdly, only few studies were available for analyses 
and this resulted in small sample size with non-significant overall effect size. 
Additionally, incomplete reporting resulted in underpowered SYNTAX analyses 
and may have introduced reporting bias. Finally, the randomised trials included 
were open-label with a potential for high performance bias. 
In conclusion, PCI with DES or CABG appear equivalent management strategies for 
LMCAD for up to 5 years with respect to death, regardless of SYNTAX score. PCI 
increases the rate of non-procedural MI at 5 years. CABG avoids the need for 
repeat revascularization, especially in diabetics, but this benefit is offset by a 
higher rate of stroke in the first year of follow up, that is likely procedure-driven. 
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Longer-term follow-up is required to examine whether additional differences 
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Figure 1: Death with PCI with DES versus CABG in randomised studies in 
LMCAD 






























Figure 2: Myocardial infarction with PCI with DES versus CABG in 
randomised studies in LMCAD 






























Figure 3: Repeat revascularization with PCI with DES versus CABG in 
randomised studies in LMCAD 






























Figure 4: Stroke with PCI with DES versus CABG in randomised studies in 
LMCAD 
(A) 1 year, (B) 3 years and (C) 5 years 
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